Ventas Inc (VTR)

Sep 27, 2026

Ventas, Inc. (VTR) is set to report its second-quarter 2026 results on July 29, with analysts expecting year-over-year growth in revenues and normalized FFO per share, driven by strong performance in its senior housing operating portfolio and outpatient medical research portfolio. The Zacks Consensus Estimate for Q2 revenues is $1.67 billion, a 17.36% increase from the prior year, and FFO per share is projected to be 96 cents, up 10.34%. However, the company's triple-net leased properties and high interest expenses might present challenges.

Sep 23, 2026

Andra AP fonden significantly increased its stake in Ventas, Inc. (NYSE:VTR) by 514.0% in the second quarter, acquiring an additional 106,902 shares. This brings their total holdings to 127,700 shares, valued at $11.34 million. Other institutional investors have also adjusted their positions in the real estate investment trust, which reported strong second-quarter earnings, beating analyst expectations and showing a 21.7% revenue increase year-over-year.

Sep 22, 2026

Ventas (VTR) is highlighted as an investment-grade senior and outpatient REIT with a strong growth thesis, supported by consistent earnings beats and positive FFO trends. The company boasts a geographically diverse portfolio and robust dividend coverage. While risks like operator concentration and valuation exist, the potential for upside and outperformance justifies a bullish stance.

Sep 21, 2026

Nykredit A/S recently acquired 131,738 shares of Ventas, Inc. (NYSE:VTR) worth $11.7 million, making a new investment in the healthcare REIT. Ventas exceeded Q2 earnings expectations with $0.97 EPS and $1.73 billion in revenue, up 21.7% year-over-year. The company declared a quarterly dividend of $0.52 per share and has a "Moderate Buy" consensus rating from analysts with an average price target of $99.11.

Sep 19, 2026

Ventas, Inc. (VTR), a healthcare real estate investment trust with a market cap of $45.2 billion, has shown strong performance, outpacing the broader real estate sector (XLRE) over both three months and 52 weeks. The company recently reported better-than-expected Q2 2026 earnings, and analysts currently rate the stock as a "Strong Buy" with significant upside potential.

Sep 16, 2026

Corient Private Wealth LP significantly increased its stake in Ventas, Inc. (NYSE:VTR) by 114.8% during the second quarter, bringing its total holdings to $15.13 million. This comes as other large institutional investors also adjusted their positions, and several Wall Street analysts have issued "Buy" or "Outperform" ratings for the real estate investment trust, with a consensus target price of $99.11. Ventas recently reported earnings that topped analyst estimates and declared a quarterly dividend.

Sep 15, 2026

Ventas, Inc. (NYSE:VTR) has declared a quarterly dividend of $0.52 per share, payable on October 15th to shareholders of record on September 30th. While the current payout ratio of 270.1% suggests the dividend isn't fully covered by current earnings, analysts anticipate a future payout ratio of 48.5% based on next year's earnings. The company recently exceeded revenue and EPS estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $99.00.

Sep 12, 2026

Baird Financial Group Inc. significantly increased its stake in Ventas, Inc. (NYSE:VTR) by 39.8% in the second quarter, adding 64,687 shares to own 227,174 shares valued at $20.2 million. Ventas, a real estate investment trust focused on healthcare properties, reported strong quarterly earnings, beating analyst expectations with adjusted EPS of $0.97 and revenue of $1.73 billion, a 21.7% year-over-year increase. Analysts maintain a "Moderate Buy" rating for VTR, with an average price target of $99.00, suggesting potential upside from its current trading price of $90.10.